Clinical trial · Observational
Impact of Bevacizumab on Symptom Burden and Neurological Deficits in Patients With Recurrent Glioblastoma
Impact of Bevacizumab on Symptom Burden and Neurological Deficits in Patients With Recurrent GBM: A Retrospective Patient Chart Review
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This retrospective non - interventional patient chart review will be utilizing real world clinical data from patients treated for rGBM at the University Regensburg Medical center either with or without bevacizumab. Only patients will be analyzed who were potentially eligible for bevacizumab treatment. The study is designed to investigate the potential effects of bevacizumab treatment on the functional status, symptom burden, neurological deficits, time to tumor progression and overall survival between cohorts potentially eligible for bevacizumab.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Angiogenesis | — | UNRESOLVED | — |
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Observation of neurological deficits | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- A
- description
- Treatment without bevacizumab
- interventionNames
- Other: Observation of neurological deficits
- label
- B
- description
- Treatment with bevacizumab
- interventionNames
- Other: Observation of neurological deficits
Primary outcomes (1)
- measure
- Functional outcome
- timeFrame
- 15 months
- description
- Neurological deficits impacting functional independency
Eligibility
Eligibility (as posted)
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Diagnosis of recurrent glioblastoma Exclusion Criteria: Severe neurocognitive deficits
References
Publications (0)
Data not yet available